More than 10 thousand experts and specialists in infertility will meet at the beginning of July in Helsinki. Participants of the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) held in Finland will share their knowledge and discuss the latest trends in the diagnosis and treatment of infertility. The conference is traditionally accompanied by the exhibition of the medical and biotechnological companies. INVICTA Genetic Laboratory, for the third time, will present its services based on innovative next generation DNA sequencing (NGS).
Annual Meeting of ESHRE is dedicated to promoting the exchange of experience and current knowledge in the field of reproductive medicine. It is one of the most important infertility related events in the world. Before and during the congress our experts will share their achievements and opinions. Prof. Krzysztof Łukaszuk, MD, PhD and Sebastian Pukszta, PhD will deliver lectures that including presentations of key findings from research projects performed at our clinics – says Jakub Dejewski, Sales and Marketing Director at INVICTA. During the exhibition participants will be able to learn the results of latest research, new tools and offerings from companies supporting the daily clinical practice.
INVICTA Genetic Laboratory will be among the companies promoting the most innovative genetic testing. In Poland it is a leading provider of preimplantation genetic diagnosis (PGD). In 2013, as the first center in the world, INVICTA introduced embryo testing based on the next generation sequencing into clinical practice. It is the most advanced and precise technique used for genetic analysis. During the ESHRE Exhibition, in addition to its core services, it will present its new personalized genetic diagnosis options for adult patients.
INVICTA Genetic Laboratory is a leader in innovative testing of human DNA in Poland. We have many accomplishments in the implementation of next generation sequencing. We will certainly talk about them. We also want to promote more widely preimplantation genetic screening PGS NGS – says Jakub Dejewski. It is worth noting that the quality of testing offered by INVICTA has been confirmed by international quality assessments including EMQN (European Molecular Genetics Quality Network), CF Network (Cystic Fibrosis European Network), Instand, QCMD (Quality Control for Molecular Diagnostics), CEQA (Cytogenetic European Quality Assessment) and Labquality.